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Objective. The purpose of this study was to analyze the efficacy 
and safety of intravenous amiodarone in young patients with 
critical, drug-resistant arrhythmias. 
Background. Intravenous amiodarone has been investigated in 
adults since the early 1980s. Experience with the drug in young 
patients is limited. A larger pediatric study group was necessary to 
provide responsible guidelines for the drug's use before its market 
release. 
Methods. Eight centers obtained institutional approval of a 
standardized protocol. Other centers were approved on a compas- 
sionate use basis after contacting the primary investigator 
(J.C.P.). 
Results. Forty patients were enrolled. Standard management in
all failed. Many patients had early postoperative taehyarrhyth- 
mias (25 of 40), with early successful treatment in 21 (84%) of 25. 
Twelve patients had ventrieular tachyarrhythmias: seven had 
successful therapy, and six died, none related to the drug. Eleven 
patients had atrial tachyarrhythmias: 10 of 11 had immediate 
success, but 3 later died. Fourteen patients had junctional ectopic 
tachycardia, which was treated with success (sinus rhythm or 
slowing, allowing pacing) in 13 of 14, with no deaths. Three other 
patients had supraveutricular tachycardias, with success in two 
and no deaths. The average loading dose was 6.3 mg/kg body 
weight, and 50% of patients required a continuous infusion. Four 
patients had mild hypotension during the amiodarone bolus. One 
postoperative patient experienced bradycardia requiting tempo- 
rary pacing. There were no proarrhythmic effects. Deaths (9 
[23%] of 40) were not attributed to amiodarone. 
Conclusions. Intravenous amiodarone is safe and effective in 
most young patients with critical tachyarrhythmia. Intravenous 
amiodarone can be lifesaving, particularly for postoperative junc- 
tional ectopic tachycardia, when standard therapy is ineffective. 
(J Am Coll Cardiol 1996;27:1246-50) 
Studies of the use of intravenous amiodarone in adult (1,2) and 
pediatric patients (3) have shown the drug to be of benefit in 
settings where a rapid antiarrhythmic effect is desirable. Oral 
administration of amiodarone has proved effective in the 
control of a number of resistant arrhythmias in children and 
young adults, particularly atrial flutter (4-6), junctional tachy- 
cardia (7) and ventricular arrhythmias (8). Mthough relatively 
rapid adequate serum levels and clinical electrophysiologic 
effects have been documented with high dose oral loading (9), 
the oral route generally requires everal days (10) to produce 
the desired antiarrhythmic result. 
In a previous report (3), amiodarone was shown to be well 
tolerated in a small series of pediatric patients, particularly 
those who had undergone r pair of a congenital heart defect. 
In that study, the drug was used for its acute action to 
terminate achyarrhythmias. In a more recent study, Figa et al. 
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(11) reported their experience with many patients receiving 
intravenous amiodarone to prevent recurrences after conver- 
sion of the primary arrhythmia. 
The purpose of the present study was to examine a larger 
series of patients of pediatric age in a multicenter p otocol to 
determine the optimal use of the agent in the acute termina- 
tion of critical, drug-resistant tachyarrhythmias, e pecially in 
postoperative congenital heart patients. 
Methods  
A total of eight pediatric enters underwent the process of 
obtaining Institutional Review Board approval for the current 
study. Criteria for enrollment ofpatients included the presence 
of a potentially ife-threatening cardiac arrhythmia that did not 
respond to conventional therapy or in which conventional 
forms of therapy were judged to carry risk of significant 
deleterious adverse ffects. No patient would receive intrave- 
nous amiodarone asa first-fine agent. Patients were enrolled at 
approved institutions by the attending pediatric ardiologist 
and at other institutions on a compassionate use basis after 
review and approval by the principal investigator (J.C.P.). 
Written informed consent was obtained, as was emergency 
Institutional Review Board approval for "compassionate use" 
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Table 1. Success Rate Versus Anatomy and Tachyarrhythmia Type 
Other 
Cardiac Anatomy (no.) VT VT/VF AutoAT IART JET SVT Total 
Postop Fontan (8) 1/2 5/5 0/1 6/8 
Postop VSD or AVC (6) 0/1 4/5 4/6 
Myocarditis (4) 1/2 2/2 3/4 
Hamartoma/rhabdo (4) 3/3 1/1 4/4 
Postop TAPVR (3) 2/2 l/l 3/3 
Postop arterial switch (2) 1/1 i/1 2/2 
Postop truncus (2) 1/1 1/1 2/2 
Postop tetralogy (2) 1/l 1/1 2/2 
Hypertrophy CM (2) i/1 1/1 2/2 
Dilated CM (2) 1/1 0/1 1/2 
Normal (2) 1/1 0/1 1/2 
Others (3) 1/1 0/1 1/1 2/3 
Total (40) 6/7 2/5 6/6 4/5 13/14 1/3 32/40 
Data presented are number of patients with successful treatment/total patients treated. AutoAT = automatic atrial 
tachycardia; AVC = atrioventricular canal defects; CM = cardiomyopathy; IART = intraatrial reentrant tachycardia; 
JET = junctional ectopic tachycardia; Postop = postoperative; rhabdo - rhabdomyoma; SVT = supraventricular 
tachycardia; TAPVR = total anomalous pulmonary venous return; VF = ventricular fibrillation; VSD - ventricular 
septal defect; VT - ventricular tachycardia. 
patients. This report does not include 10 patients from a 
preliminary study, reported previously (3). 
Protocol. Intravenous amiodarone hydrochloride in a con- 
centration of 150 rag/3 ml was supplied by Wyeth Ayerst 
Laboratories. The drug protocol included bolus administration 
of amiodarone ata dose of 5 mg/kg body weight, divided into 
five 1-mg/kg aliquots, each given over 5 to 10 rain. The drug 
was diluted in 5% dextrose water. Each patient received the 
full 5-mg/kg loading dose, even if termination of the tachyar- 
rhythmia was observed before the full bolus had been given. At 
the discretion of the physician, an additional 1- to 5-mg/kg 
bolus could be given in the same manner 30 rain later, if 
needed. A continuous infusion of amiodarone at 10 to 
15 mg/kg per day could be used, again at the discretion of the 
physician at each site. The drug was protected from light 
exposure during infusion. A crossover to oral amiodarone, 
when used, included a 1- to 2-day overlap of intravenous and 
oral therapies. Because these arrhythmias occurred in a critical 
care setting, blood pressure was monitored continuously by 
arterial ine in nearly all patients. Before the amiodarone 
bolus, serum electrolytes, complete blood count and thyroid 
and liver function tests were obtained. 
Results from the preliminary study (3) were so impressive 
compared with historical accounts for these critical arrhyth- 
mias that a case-control r blinded format for the current study 
was considered inappropriate. These preliminary results, and 
the need for urgent antiarrhythmic therapy, dictated the use of 
an "intention to treat" approach. "Success" of therapy for this 
study was defined as acute termination ofthe arrhythmia or, in 
the case of junctional ectopic tachycardia, termination or 
slowing to an acceptable rate to allow hemodynamic improve- 
ment with atrial or atrioventricular (AV) sequential pacing. 
Statistical analysis. The Student test and contingency 
table analysis with chi-square test were used when appropriate. 
The level of significance was 5%. 
Resu l ts  
Patient demographics. The 17 centers enrolling patients 
are listed in the Appendix. A total of 40 patients were enrolled 
in the period from June 1993 through March 1995. The 
average patient age was 5.4 years, and 24 of 40 were <2 years 
old. Arrhythmias in the immediate postoperative p riod after 
congenital heart surgery were present in 25 (63%) of 40 
patients. No patient received amiodarone as a first-line drug. 
Dosing and adverse effects. The average loading dose was 
6.3 mg/kg. A continuous infusion was administered in 21 of the 
40 patients as follows: 8 of 12 with ventricular tachycardia, 7 of 
11 with atrial tachycardia, 3 of 14 with junctional ectopic 
tachycardia and 3 of 3 with other forms of supraventricular 
tachycardia. The duration of infusion therapy averaged 2.5 
days. Only seven patients (three with ventricular tachycardia, 
three with atrial tachycardia, one with nonpostoperative junc- 
tional ectopic tachycardia) were converted to oral amiodarone 
therapy, with an average overlap of 1.8 days. No patient 
responded to the first 1-mg/kg bolus. 
Adverse effects attributed to intravenous amiodarone ad- 
ministration were seen in four patients. All four had transient 
hypotension during the bolus phase. There was no predilection 
for arrhythmia type or patient age, and no patient had an 
adverse effect within the first 2-mg/kg total bolus. In each 
instance, the hypotension was mild and responded to volume 
or calcium chloride administration, or both. There were no 
cases of proarrhythmic effects or AV block, and one postop- 
erative patient required transient pacing for bradycardia. No 
acute changes were seen in liver or thyroid profiles. Eleven 
patients in this series died and are discussed subsequently. 
Cardiac anatomy versus arrhythmia. The underlying car- 
diac defects een in this patient group are shown in Table 1 
with the corresponding observed tachyarrhythmias. Thirty-two 
(80%) of the 40 patients had early success with intravenous 
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Table 2. Ages and Outcomes of Patients With 
Various Tachyarrhythmias 
Average 
Arrhythmia No. Success Age Postop Deaths 
VT 12 8 9.2 yr* 4/12 6 
AutoAT 6 6 5 mo 2/6 3 
IART 5 4 14.5 yrt 4/5 1 
JET 14 13 18 mo 13/14 1 
Other SVT 3 1 3.8 yr 2/3 1 
*p = 0.02 for age of patients with ventricular t chycardia versus average age 
of 3.6 years for patients without ventricular tachycardia (t test), tp < 0.05 for 
patients with intraatrial reentrant tachycardia versus those with automatic atrial 
tachycardia (chi-square). Abbreviations as in Table 1. 
amiodarone. Postoperative patients with a Fontan procedure 
comprised the greatest number in the series, predominantly 
manifesting junctional ectopic tachycardia. 
Ventricular tachycardias. There were 12 patients with 
ventricular tachycardias. As shown in Table 2, the average age 
of these patients, 9.2 years (95% confidence interval [CI] 5.5 to 
12.9), was significantly greater (p = 0.02, t test) than that for 
study patients without ventricular tachycardia ( verage age 3.6 
years, 95% CI 1.2 to 6.0). Early postoperative ventricular 
arrhythmias occurred in only 4 of these 12 patients as opposed 
to the remaining 28, of whom 21 had early postoperative 
arrhythmias (p < 0.05, chi square). Overall, 8 of 12 patients 
responded immediately to intravenous amiodarone. All three 
patients with cardiac tumors and ventricular tachycardia re- 
sponded to intravenous amiodarone. Seven patients had 
monomorphic ventricular tachycardia, six of whom responded 
favorably during the bolus phase. Three of these patients died 
subsequently: one 8-month old with myocarditis in whom 
therapy was unsuccessful, one 13-year old with previously 
suspected brain death after operation and one ll-year old with 
a myxoma nd sepsis. Five patients had polymorphic ventric- 
ular tachycardia or both ventricular tachycardia and ventricu- 
lar fibrillation. Only two of these five patients responded, and 
three died. The deaths included one 8-month old trauma 
victim, one teenage nonresponder with ventricular tachycardia 
after AV canal repair with mitral replacement and a 7-year old 
who responded but died while awaiting transplantation for 
dilated cardiomyopathy. 
Atrial tachyarrhythmias. There were 11 patients with 
atrial tachyarrhythmias. Sixhad automatic mechanisms, and all 
six responded to intravenous amiodarone. Three responded 
immediately during amiodarone bolus, and the other three had 
gradual slowing during infusion before sinus rhythm. The 
automatic atrial tachycardia patients were young, averaging 5
months of age. There were two deaths: one newborn with 
complex total anomalous pulmonary venous return and a 
12-day old with myocarditis. 
Five patients had intraatrial reentrant atrial tachycardias, 
and four responded to intravenous amiodarone, two immedi- 
ately during the bolus. One patient, a 12-week old with sepsis 
after arterial switch operation for transposition, died later. 
Junctional ectopic tachycardia. Fourteen patients had 
junctional ectopic tachycardia. All but one had postoperative 
junctional ectopic tachycardia, with the majority (10 of 14) 
occurring after the Fontan operation, ventricular septal defect 
closure or AV canal repair. Every patient had a trial of cooling, 
and all had received igoxin or procainamide, or both, before 
amiodarone. Procainamide had been discontinued in all but 
two patients. The patients with junctional ectopie taehycardia 
were young, with an average age of 18 months. Intravenous 
amiodarone was immediately successful in 13 (93%) of 14. Five 
of these 13 converted to sinus rhythm, and 8 patients had 
sufficient slowing of the junctional ectopic tachycardia to allow 
improved hemodynamic function using atrial or AV sequential 
pacing at an acceptable rate. All 13 had a beneficial effect 
observed uring the initial bolus of amiodarone (between 2
and 5 mg/kg of total bolus). One patient died a nonarrhythmic 
death 3 months later, off amiodarone. 
Other supraventricular tachycardias. Three other forms 
of supraventricular tachycardia were treated with intravenous 
arniodarone. An orthodromic supraventricular t chycardia n a 
5-day old with probable rhabdomyomas had successful ther- 
apy. Two other patients failed to improve significantly on 
amiodarone: a 10-day old with permanent junctional recipro- 
cating tachycardia (who subsequently underwent radiofre- 
quency ablation) and a 5-year old postoperative patient with a 
hemi-Fontan procedure with orthodromic supraventricular 
tachycardia (who died later). 
Deaths. Eleven (28%) of the 40 patients died. The time 
from administration of intravenous amiodarone to time of 
death ranged from 3 h to 3 months. Two patients died 3 h after 
amiodarone, and both were infants with myocarditis. Two 
other patients died who did not receive amiodarone for <2 
days. All other deaths were in patients not receiving amioda- 
rone from the time of bolus administration for >2 days. None 
of the deaths in this series were judged by the treating 
physician to be related to amiodarone administration. 
Discuss ion 
Therapeutic options for critical tachyarrhythmias re lim- 
ited. When standard therapies such as cardioversion, overdrive 
pacing and available intravenous antiarrhythmic agents, fail or 
are undesirable or unavailable, conversion of hemodynamically 
unstable rhythms is problematic. The immediate antiarrhyth- 
mic action of intravenous amiodarone in the 40 patients in this 
report led to an acute resolution of tachycardia with improved 
hemodynamic function in 32 (80%), without serious adverse 
effects, such as proarrhythmia or sustained hypotension. 
Junctional ectopic tachycardia. One of the most important 
findings in this study is the dramatic response of postoperative 
junctional ectopic tachycardia to intravenous amiodarone. 
Postoperative junctional ectopic tachycardia s one of the most 
resistant and life-threatening of tachyarrhythmias encountered 
in pediatric cardiology. Standard first-line therapies tend to 
include core temperature cooling, intravenous digoxin, intra- 
venous procainamide, atrial or AV sequential pacing at a faster 
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rate and removal of exacerbating factors, such as pressor 
agents and vagolytic drugs (12). Despite these interventions, 
junctional ectopic tachycardia often persists and results in a 
loss of AV synchrony, which is especially compromising in the 
patient with single-ventricle physiology. Core temperature 
cooling results in peripheral vasoconstriction, which can con- 
tribute to acidosis, and shivering from cooling can increase 
oxygen consumption. Intravenous agents other than digoxin 
can reduce myocardial contractility. The overwhelmingly pos- 
itive and rapid response of this group of patients to intravenous 
amiodarone, 93% in this report, is very encouraging and raises 
the possibility of using the drug as first-line therapy for 
postoperative junctional ectopic tachycardia. With the usual 
time course for junctional ectopic tachycardia of 2 to 3 days, 
many patients required only single or intermittent bolus ther- 
apy and did not need infusion or chronic oral therapy. 
Tumors and myocarditis. Arrhythmias in patients with 
hamartomas and rhabdomyomas re generally difficult to 
control and often require surgical intervention (13). Four 
patients in this study had cardiac tumors. The three patients 
with ventricular tachycardia and one patient with orthodromic 
supraventricular tachycardia allhad immediate control of their 
arrhythmia with intravenous amiodarone. 
Four other patients had clinical evidence of myocarditis: 
two with ventricular tachycardia and two with automatic atrial 
tachycardia. All four of these patients presented with ex- 
tremely poor ventricular function. Two of these patients died, 
one without response of ventricular tachycardia toamiodarone 
and one with automatic atrial tachycardia who required pro- 
longed extracorporeal membrane oxygenation, responded to 
intravenous amiodarone, but died later. 
Adverse events and deaths. In the recent study by Figa et 
al. (11), many oung patients were not in tachycardia (17 of 30 
cardioversions) atthe time they received intravenous amioda- 
rone, and the drug was used primarily to prevent arrhythmia 
recurrences. A high incidence of "adverse vents" was noted in 
18 (58%) of 30 patients in their series, but these events 
included bradycardia requiring pacing (a therapeutic goal in 
the postoperative patient with junctional ectopic tachycardia) 
in 5 of 18 patients who were receiving both propafenone and 
amiodarone and any patients who had an adverse vent on 
subsequent oral amiodarone. In contrast, the present study 
examined a cohort in whom intravenous amiodarone was used 
to terminate achyarrhythmias immediately in each. No patient 
was given a class IC drug concurrently. 
Eleven patients in the present study died. Four of these 11 
died within 2 days of receiving intravenous amiodarone. There 
were no cases of proarrhythmia, ncluding exacerbation ofthe 
initial arrhythmia, nd no cases of drug-induced AV block. 
Study limitations. Although a similar protocol was used at 
every institution, there are obviously differences in therapeutic 
approach in some centers and different concepts of standard 
therapy. Despite this drawback, prior therapeutic interventions 
for arrhythmias in this setting were surprisingly uniform. This 
study was clearly based on an "intention-to-treat" pproach 
rather than a case-control format, which biases analysis toward 
favorable results. 
Conclusions and recommendations. Intravenous amioda- 
rone was safe when administered slowly to young patients with 
critical tachyarrhythmias. There were excellent responses in 
patients with postoperative junctional ectopic tachycardia and 
atrial tachycardia. The transient hypotension seen in four 
patients was addressed with volume expansion and calcium 
chloride without incident. 
Patients receiving intravenous amiodarone should have 
arterial pressure monitored and have backup acing available. 
Although significant bradycardia requiring prolonged pacing 
did not occur in this study, the need for pacing is particularly 
helpful from a therapeutic standpoint in the patient with 
postoperative junctional ectopic tachycardia. Because there 
were no immediate antiarrhythmic or adverse ffects with the 
first 1- to 2-mg/kg doses, it is likely that the drug could be 
administered as 2- to 3-mg/kg boluses over 5 rain to a total oad 
of 10 mg/kg in young patients. Intravenous amiodarone s ems 
to be a reasonable choice as first-line therapy for postoperative 
junctional ectopic tachycardia. Additionally, it may be a good 
drug for slower but accelerated junctional rhythms in postop- 
erative patients with a single-ventricle, where maintenance of 
AV synchrony iscrucial, and other intravenous antiarrhythmic 
agents can compromise ventricular function. Continued anal- 
ysis of the use of intravenous amiodarone inyoung patients i  
needed to determine if it may be prudent o use the drug 
earlier in less critically ill patients to reduce potential morbid- 
ity. 
We thank Gilbert Rose, MD, of Wyeth-Ayerst Research Laboratories forhis 
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Appendix 
Participating Centers and Investigators for the 
Pediatric Electrophysiology Group Study 
Children's Hospital San Diego (James C. Perry, MD), Texas Children's 
Hospital (Richard A. Friedman, MD), Children's Hospital Boston (John IC 
Triedman, MD), Atlanta Children's Heart Center (J. Edward Hulse, MD), 
Geisinger Medical Center (Mark Cohen, MD), Stanford University Medical 
Center (Ruey Sung, MD), Louisville (Christodulos Stavens, MD), Children's 
Heart Clinic, Minneapolis (David Burton, MD), Yale University Medical Center 
(Roberto Neghme, MD), Medical College of Ohio (Blair Grubb, MD), Hershey 
Medical Center (Jerry Luck, MD), University of California, San Francisco 
(George F. Van Hare, MD), St. Vincent's Hospital, Los Angeles (William 
Vincent, MD), Johns Hopkins University (John Lawrence, MD), University of
Washington, Seattle (Paul Herndon, MD), University ofArkansas, Little Rock 
(Christopher E ickson, MD), Georgetown U iversity Hospital (Stan Beder, 
MD). 
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